Materials for the Administration of Human Genetic Resources
Release Date:
2023-03-30 16:57
I. Approval for the Collection of Human Genetic Resources in China
Application Form Template Download:
https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/Collection_of_Audits.zip
II. Approval for the Preservation of China’s Human Genetic Resources
Application Form Template Download: https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/Quality Assurance Template.doc
III. Approval for International Collaborative Scientific Research Involving China’s Human Genetic Resources
Application Form Template Download: https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/National_Collaborative_Science_and_Technology_Research_Accreditation.zip
IV. Approval for the Export of China’s Human Genetic Resources
Application Form Template Download:
https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/Materials_Review.zip
V. Filing of International Collaborative Clinical Trials Involving China’s Human Genetic Resources
Application Form Template Download: https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/National Joint Testing Project Template.doc
VI. Filing for the External Provision or Open Access to Information on China’s Human Genetic Resources
Application Form Template Download: https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/Information_Sheets_and_Folders.zip
VII. List of Materials to Be Submitted via the Online Filing System
1 Application Form (Attachment)
2. The business license or organizational code certificate, and the legal person certificate of this entity
3. Supporting documentation specifying the Chinese-side and foreign-side institutions
Application Form Template Download:
https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/ktwssbxttjclqd.docx
Related News
This training program focuses on the regulatory standards governing the manufacturing of cell therapy products and the clinical research and translational applications of cutting-edge biomedical technologies, attracting participants from enterprises, research institutes, clinical institutions, and industry-chain representatives across the country. Standardization is the fundamental cornerstone for ensuring that these products are safe, effective, and accessible. As a one-stop upstream cell solutions provider offering primary cell services, pharmacological efficacy services, and product services, Heyousheng looks forward to engaging in in-depth exchanges with industry experts and peers.
3.0 High-Efficiency NK Serum-Free Culture Kit | Chapter 3: CBNK Competitor Comparison
HeYouSheng Bio’s 3.0 High-Efficiency HiXpan® NK Serum-Free Culture Kit is manufactured in strict compliance with GMP standards, and its production system adheres to relevant guidelines, including the “818 Requirements,” making it suitable for pharmaceutical-grade manufacturing and applications. In response to extensive customer demand, we have conducted a comparative analysis of culture performance against two leading commercial competitor media.
3.0 High-Efficiency NK Serum-Free Culture Kit | Chapter 2: PBNK Derived from Peripheral Blood
HeYouSheng Biotechnology’s newly launched 3.0 High-Efficiency Serum-Free NK Cell Culture Kit (Catalog No.: NK888-2L), in collaboration with the PBMC Seed Bank, provides a comprehensive, integrated cell culture solution: from thawing and recovering PBMC seed stocks or directly and efficiently expanding fresh PBMCs, to ultimately obtaining NK cells with high purity and high viability.
HeYouSheng Biotechnology, in collaboration with Boteng Biotechnology, has pioneered the launch of PBMCs that comply with both GMP standards and the dual China–U.S. regulatory submission requirements, thereby establishing a robust compliance foundation for iPSC reprogramming right at the source. The notion of “starting from ‘zero’” not only signifies the proactive avoidance of compliance risks from the very outset of R&D, but also reflects the establishment by the two companies of a comprehensive, end-to-end compliance closed-loop that spans the entire process—from donor screening and sample collection to isolation, preparation, and quality control.
818 Breakthrough Technology | Integrated Culture Protocol for γδ T Cells
The implementation of the “818 Regulations” marks the official entry of China’s cell therapy industry into a new phase of standardized development, one that prioritizes clinical efficacy as the benchmark for value, upholds rigorous compliance across the entire process as an inviolable baseline, and centers on differentiated technological innovation as the core driver. The Regulations explicitly restrict low-level duplication and homogeneous competition, while giving priority to the translation of technology pathways that demonstrate clear clinical value and outstanding scientific innovation, thereby establishing clear compliance boundaries and innovation-oriented guidance for the future direction of the industry.
Conference Announcement | Hycells cordially invites you to join the 3rd Boao Lecity Stem Cell Summit
From March 20 to 22, 2026, the Third Boao Lecity Stem Cell Conference, co-hosted by the China Anti-Aging Promotion Association and Hainan University, will be held in Boao Lecity, Hainan. With the theme “Cell Therapy Pioneering the Third Medical Revolution,” the conference will also make a major announcement of the latest batch of cell therapy procedures that are now permitted to be billed, thereby establishing an international high-end platform that brings together cutting-edge ideas, translates research into clinical practice, fosters industry collaboration, and jointly develops policies and standards.